Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Article information

Intest Res. 2020;18(3):343-344
Publication date (electronic) : 2020 July 20
doi : https://doi.org/10.5217/ir.2018.00078-c1
1Department of Pharmacy and Kitasato University Kitasato Institute Hospital, Tokyo, Japan
2Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
3The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

https://doi.org/10.5217/ir.2018.00078

Intest Res 2019;17(1):87-93

In the version of this article initially published, Figure 2 contains errors in the content of the questionnaire.

On page 89, the figure should be corrected as following.

From:

Fig. 2.

(A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.

To:

Fig. 2.

(A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.

Article information Continued

Fig. 2.

(A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.

Fig. 2.

(A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.